imho this is a non event when you take into consideration the number of shares insiders have purchased over the last year. a 20k share sell pails in comparison to the 1M+ insiders have purchased. volume will continue to increase as we near the PhIII data.
JR Hyde does have a lot of Autozone funny money, but Dalton is the axe when it comes to SARMs. Merck is on record not liking the NSCLC setting for SARMs. Add this the lack of a SPA or any new commercial partner, and these data points suggests choppy water ahead.
Technical resistance at this $5 range, but fair support at the $4 range.
According to a company press release, Dalton assumed more responsibilities but no pay increase. The options were part of the pay package. He obviously viewed it that way. So no, not exactly bearish either.